Second primary cancers and hormonal therapies for prostate cancer: A nested case-control study.

ABSTRACT:

Introduction

(Pre-)clinical studies have not ruled out a potential risk of second primary cancer (SCP) under the effect of some new androgen receptor pathway inhibitors (ARPIs), especially enzalutamide (ENZ).

Methods

Using the French health reimbursement claims database (Système National des Données de Santé), we designed a case-control study nested in a 2013-2020 cohort of new users of androgen-deprivation therapy. The cases were patients with a first diagnosis of SPC, identified beyond 12 months following cohort entry and up to December 31st^, 2021; up to 10 controls were matched per case, based on age and cohort entry date. The main analysis focused on patients who had not switched to a different ARPI. Applying a one-year lag time, we determined the most frequen

SUBMITTER: Scailteux LM 

PROVIDER: S-EPMC11913542 | biostudies-literature | 2025 Apr

REPOSITORIES: biostudies-literature